THERAVIA is a European-based company dedicated to the development, marketing, and distribution of innovative and original products dedicated to serious conditions, rare diseases, and unmet medical needs. Formed in 2023 through the merger of two French companies (ADDMEDICA and CTRS), they benefit from their track records in drug development, registration, and commercialization, as well as from a strong hospital presence and a solid KOL network, especially for rare disorders. They also benefit from a robust commercial network in all countries of Western Europe.

They are supported by MERIEUX EQUITY PARTNERS as a reference shareholder to accelerate their growth in France and internationally. To expand their portfolio, they are now looking for new products with the following features:

– Designed to treat a limited number of patients

– And/or highly innovative products

– And/or addressing emerging markets with few competitors and requiring specialized sales & distribution processes

Theravia is a leader in some rare diseases’ treatment, having, for example, marketed a safe and easy-to-dose form of hydroxyurea called « Siklos » in Europe, the US (https://siklosusa.com/), and other territories to treat sickle cell disease. They invest in large clinical trials to advance the knowledge of the disease and its treatment. For instance, they are conducting ESCORT-HU, a Phase IV observational cohort study that includes more than 2,000 patients.

–  Therapeutic areas: Rare diseases, Neglected disorders, Paediatric diseases

–  Based in: Ile de France (FRANCE)

–  Employees: 11 -50

– Created in: 2005